| Date | Title | Description |
| 28.08.2026 | Aqilion has received an indicative offer for the company | Aqilion has received an indicative offer for the company
Fri, Aug 28, 2026 16:10 CET Report this content
AQILION AB (publ) announces that the Company has received an indicative offer for all shares in the Company.The offer is a result of Aq... |
| 18.06.2026 | Resolutions from AQILION AB (publ) Annual General Meeting 2026 | Resolutions from AQILION AB (publ) Annual General Meeting 2026
Thu, Jun 18, 2026 09:30 CET Report this content
AQILION AB (publ) held its Annual General Meeting June 17, at which the meeting decided in accordance with the proposals presente... |
| 12.05.2026 | Aqilion publishes Annual Report for 2025 | Aqilion publishes Annual Report for 2025
Tue, May 12, 2026 13:57 CET Report this content
AQILION AB (publ) hereby announces that the Swedish version of the 2025 Annual Report has been published.
The Annual Report, which is attached in Swedi... |
| 20.03.2026 | Aqilion to Present Preclinical Data at Digestive Disease Week, May 2–5, Demonstrating That AQ280 Counteracts Dysfunctional Epithelial Barrier Function in Eosinophilic Esophagitis | Aqilion to Present Preclinical Data at Digestive Disease Week, May 2–5, Demonstrating That AQ280 Counteracts Dysfunctional Epithelial Barrier Function in Eosinophilic Esophagitis
Fri, Mar 20, 2026 09:00 CET Report this content
Aqilion today... |
| 18.03.2026 | Aqilion sharpens focus on AQ280 and AQ128 – ready for the next phase in inflammatory diseases | Aqilion sharpens focus on AQ280 and AQ128 – ready for the next phase in inflammatory diseases
Wed, Mar 18, 2026 14:23 CET Report this content
Aqilion announces that the company has decided to focus on two of its pipeline projects; drug cand... |
| 16.10.2025 | Positive Results from Clinical Pharmacokinetic Study for the Eosinophilic Esophagitis Specific Formulation with the Drug Candidate AQ280 | Positive Results from Clinical Pharmacokinetic Study for the Eosinophilic Esophagitis Specific Formulation with the Drug Candidate AQ280
Thu, Oct 16, 2025 10:30 CET Report this content
Aqilion today announces positive results from the ARIA-... |
| 18.07.2025 | Aqilion finalizes the eosinophilic esophagitis specific formulation pharmacokinetic study with the drug candidate AQ280 | Aqilion finalizes the eosinophilic esophagitis specific formulation pharmacokinetic study with the drug candidate AQ280
Fri, Jul 18, 2025 11:16 CET Report this content
Aqilion AB is pleased to announce the completion of its second Phase 1 c... |
| 06.06.2025 | Aqilion's Bold Steps in Biotech: A New Era for Chronic Inflammation Treatment | Aqilion AB is making waves in the biotech world. The company recently unveiled promising preclinical data for its TAK1 program, a potential game-changer in treating chronic inflammation. This innovative approach could redefine how we tackle... |
| 05.06.2025 | Aqilion Presents New Preclinical Proof-of-Concept Data for TAK1 Program | Aqilion Presents New Preclinical Proof-of-Concept Data for TAK1 Program
Thu, Jun 05, 2025 09:15 CET Report this content
Helsingborg, June 5, 2025 – Aqilion AB today announces positive results from new studies with molecules from the company... |
| 03.06.2025 | Resolutions from AQILION AB (publ) Annual General Meeting 2025 | Resolutions from AQILION AB (publ) Annual General Meeting 2025
Tue, Jun 03, 2025 19:00 CET Report this content
Helsingborg, June 3, 2025 – AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance w... |
| 12.05.2025 | Aqilion receives IND approval from FDA | Aqilion receives IND approval from FDA
Mon, May 12, 2025 08:50 CET Report this content
AQILION AB (publ) today announces that the US Food and Drug Administration (FDA) has approved Aqilion's IND (investigational new drug) application for th... |
| 06.05.2025 | Aqilion publishes Annual Report for 2024 | Aqilion publishes Annual Report for 2024
Tue, May 06, 2025 10:15 CET Report this content
AQILION AB (publ) hereby announces that the Swedish version of the 2024 Annual Report has been published.
The Annual Report, which is attached in Swedi... |
| 05.04.2025 | Aqilion's Bold Steps in Eosinophilic Esophagitis Research and Financial Growth | Aqilion AB is making waves in the biotechnology sector. The company is focused on chronic inflammation and autoimmune diseases. Recently, it presented significant findings at the Digestive Disease Week conference. This event, held from May ... |
| 04.04.2025 | Aqilion presents results from study of biomarkers in patients with Eosinophilic esophagitis (EoE) at the Digestive Disease Week conference on May 3-6 | Aqilion presents results from study of biomarkers in patients with Eosinophilic esophagitis (EoE) at the Digestive Disease Week conference on May 3-6
Fri, Apr 04, 2025 09:15 CET Report this content
AQILION AB (publ) AQILION AB (publ) presen... |
| 02.04.2025 | Aqilion announces final outcome of rights issue | Aqilion announces final outcome of rights issue
Wed, Apr 02, 2025 09:15 CET Report this content
THE INFORMATION IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED FOR RELEASE, OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITE... |
| 12.03.2025 | Aqilion extends period for subscription of ongoing rights rights issue | Aqilion extends period for subscription of ongoing rights rights issue
Wed, Mar 12, 2025 16:45 CET Report this content
THE INFORMATION IN THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, I... |
| 14.02.2025 | Aqilion's Strategic Moves: A Focus on Internal Growth and Innovation | Aqilion AB is making waves in the biotech world. The company recently announced a rights issue aimed at raising approximately SEK 26.8 million. This move is not just about numbers; it’s a strategic pivot. Aqilion is sharpening its focus on ... |
| 13.02.2025 | Aqilion divests its holding in Oncorena Holding AB | Aqilion divests its holding in Oncorena Holding AB
Thu, Feb 13, 2025 09:15 CET Report this content
AQILION AB (publ) today announces that the company has divested its entire holding in Oncorena Holding AB. The decision is in line with Aqili... |
| 12.02.2025 | Aqilion carries out a rights issue of approximately SEK 26.8 million | Aqilion carries out a rights issue of approximately SEK 26.8 million
Wed, Feb 12, 2025 09:15 CET Report this content
THE INFORMATION IN THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN ... |
| 05.02.2025 | Aqilion Resumes Development of its TAK1-Program | Aqilion Resumes Development of its TAK1-Program
Wed, Feb 05, 2025 09:15 CET Report this content
AQILION AB (publ) announces that the Company has resumed development of the its TAK1 program as the company has regained the control and ownersh... |
| 17.12.2024 | Aqilion to present at Biotech Showcase[TM] during JP Morgan week in San Fransisco | Aqilion to present at Biotech Showcase[TM] during JP Morgan week in San Fransisco
Tue, Dec 17, 2024 14:30 CET Report this content
AQILION AB (publ) today announced that it is presenting at Biotech Showcase 2025. Sarah Fredriksson, CEO, and ... |
| 05.11.2024 | Aqilion to present at the BioStock Life Science Summit, November 21 | Aqilion to present at the BioStock Life Science Summit, November 21
Tue, Nov 05, 2024 11:00 CET Report this content
The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Sarah Fredriksson wil... |
| 01.11.2024 | The Biotech Race: Innovation and Collaboration at the Forefront | In the fast-paced world of biotechnology, innovation is the name of the game. Companies are racing to develop groundbreaking therapies that can change lives. Two players in this arena, Aqilion and Kelun-Biotech, are making headlines with th... |
| 31.10.2024 | BioStock: Aqilion’s CEO: “We are driven by dealmaking and scientific data” | BioStock: Aqilion’s CEO: “We are driven by dealmaking and scientific data”
Thu, Oct 31, 2024 10:52 CET Report this content
With four independent programmes in its pipeline, the Swedish biotech Aqilion is positioned for a series of significa... |
| 30.10.2024 | The Nomination Committee has been appointed for the Aqilion Annual General Meeting 2025 | The Nomination Committee has been appointed for the Aqilion Annual General Meeting 2025
Wed, Oct 30, 2024 08:45 CET Report this content
Aqilion AB (publ) hereby announces that the Nomination Committee for the 2025 Annual General Meeting has... |
| 14.10.2024 | Aqilion presents new results from the AQ312 program (oral Ahr agonist) during UEG Week in Vienna | Aqilion presents new results from the AQ312 program (oral Ahr agonist) during UEG Week in Vienna
Mon, Oct 14, 2024 14:15 CET Report this content
AQILION AB (publ) is developing the anti-inflammatory drug candidate AQ312 for the treatment of... |
| 27.06.2024 | BioStock: Aqilion and Merck sever ties | BioStock: Aqilion and Merck sever ties
Thu, Jun 27, 2024 08:46 CET Report this content
Aqilion announced the termination of the licensing and collaboration agreement with Merck for the joint development of the TAK1 programme taking aim at c... |
| 20.06.2024 | Aqilion regains rights to TAK1 program | Aqilion regains rights to TAK1 program
Thu, Jun 20, 2024 16:00 CET Report this content
AQILION AB (publ) announces that Aqilion and Merck have decided to terminate the joint development of the TAK1 program. Data generated in the course of t... |
| 10.06.2024 | Resolutions from AQILION AB (publ) Annual General Meeting 2024 | Resolutions from AQILION AB (publ) Annual General Meeting 2024
Mon, Jun 10, 2024 19:45 CET Report this content
Helsingborg, June 10, 2024 – AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance ... |
| 17.05.2024 | Aqilion to present results at scientific events | Aqilion to present results at scientific events
Fri, May 17, 2024 11:05 CET Report this content
AQILION AB (publ) will present updates on the Company's progress and scientific results at two different scientific conferences in May. The pres... |
| 14.05.2024 | BioStock: Aqilion aims for best-in-class with new programme | BioStock: Aqilion aims for best-in-class with new programme
Tue, May 14, 2024 11:01 CET Report this content
Aqilion is in the business of discovering and developing new drug targets that could reduce the burden of chronic inflammatory illne... |
| 13.05.2024 | Aqilion expands its pipeline | Aqilion expands its pipeline
Mon, May 13, 2024 14:10 CET Report this content
AQILION AB (publ) announces an expansion of its pipeline through the nomination of PKCtheta as the target of a new immunology project.
Aqilion’s aims at the discov... |
| 08.05.2024 | Notice of Annual General Meeting in AQILION AB (publ) | Notice of Annual General Meeting in AQILION AB (publ)
Wed, May 08, 2024 10:15 CET Report this content
The shareholders of AQILION AB (publ), 556623-2095, are hereby invited to the Annual General Meeting Monday, June 10, 2024
This is a trans... |
| 07.05.2024 | Aqilion publishes Annual Report for 2023 | Aqilion publishes Annual Report for 2023
Tue, May 07, 2024 11:50 CET Report this content
AQILION AB (publ) hereby announces that the Swedish version of the 2023 Annual Report has been published.
The Annual Report, which is attached in Swedi... |
| 07.12.2023 | Aqilion presents Nomination Committee for the 2024 Annual General Meeting | Aqilion presents Nomination Committee for the 2024 Annual General Meeting
Thu, Dec 07, 2023 10:15 CET Report this content
The Nomination Committee for the 2024 Annual General Meeting has been appointed and comprises the following members:
•... |
| 30.11.2023 | Aqilion appoints Gustaf Albèrt as new CFO | Aqilion appoints Gustaf Albèrt as new CFO
Thu, Nov 30, 2023 16:15 CET Report this content
AQILION (publ) has appointed Gustaf Albèrt as the new CFO. Gustaf has solid financial experience from both smaller and larger listed groups and has wo... |
| 27.11.2023 | Sparks IPO Academy prepares new cohort for next move | |
| 30.10.2023 | Aqilion reports positive results from the ARIA-1 Phase 1 study in healthy subjects | Aqilion reports positive results from the ARIA-1 Phase 1 study in healthy subjects
Mon, Oct 30, 2023 12:20 CET Report this content
The drug candidate AQ280, an oral selective JAK1 inhibitor, was well tolerated, and the achieved single and m... |
| 14.08.2023 | Aqilion has completed Phase 1 study with AQ280 within the Regulus program | Aqilion has completed Phase 1 study with AQ280 within the Regulus program
Mon, Aug 14, 2023 10:48 CET Report this content
AQILION (publ) announces today that it has successfully completed the first clinical study in humans within the Regulu... |
| 01.06.2023 | Resolutions from Aqilion Annual General Meeting 2023 | Resolutions from Aqilion Annual General Meeting 2023
Thu, Jun 01, 2023 19:30 CET Report this content
Helsingborg, June 1, 2023 – AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance with the pr... |
| 08.05.2023 | Aqilion publishes Annual Report for 2022 | Aqilion publishes Annual Report for 2022
Mon, May 08, 2023 13:30 CET Report this content
AQILION AB (publ) hereby announces that the Swedish version of the 2022 Annual Report has been published.
The Annual Report, which is attached in Swedi... |
| 22.03.2023 | Aqilion to recieve 20.1 MSEK after conversion of outstanding warrants | Aqilion to recieve 20.1 MSEK after conversion of outstanding warrants
Wed, Mar 22, 2023 09:30 CET Report this content
In order to strengthen the company's liquidity and to ensure the continued development of the company's pipeline, on July ... |
| 06.03.2023 | Aqilion appoints Scientific Advisory Board | Aqilion appoints Scientific Advisory Board
Mon, Mar 06, 2023 11:00 CET Report this content
Aqilion today announces the formation of a Scientific Advisory Board with three key appointments: Dr. Luc Michel Biedermann, Professor Albert J Brede... |
| 16.02.2023 | Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck | Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck
Thu, Feb 16, 2023 07:30 CET Report this content
AQILION AB (“Aqilion”) today announced an exclusive license and strategic research collaborat... |
| 16.02.2023 | Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck | HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the... |
| 07.12.2022 | Aqilion presents Nomination Committee for the 2023 Annual General Meeting | Aqilion presents Nomination Committee for the 2023 Annual General Meeting
Wed, Dec 07, 2022 07:30 CET Report this content
The Nomination Committee for the 2023 Annual General Meeting has been appointed and comprises the following members: C... |
| 07.09.2022 | Aqilion has completed a rights issue | Aqilion has completed a rights issue
Wed, Sep 07, 2022 07:30 CET Report this content
AQILION AB (publ) announces today that the company has completed a rights issue with preferential rights for existing shareholders. The company will thus r... |
| 11.08.2022 | Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases | Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases
Thu, Aug 11, 2022 07:30 CET Report this content
AQILION AB (publ) announces today that the Phase 1 clinical safety study on the drug candidate... |
| 15.06.2022 | Aqilion resolves on issue in kind | Aqilion resolves on issue in kind
Wed, Jun 15, 2022 07:30 CET Report this content
AQILION AB (publ) is announcing today that the company’s Board of Directors has resolved on an issue in kind in accordance with the acquisition of the Regulus... |
| 14.06.2022 | Aqilion receives regulatory approval to conduct Phase 1 clinical trial in Regulus program within inflammatory diseases | Aqilion receives regulatory approval to conduct Phase 1 clinical trial in Regulus program within inflammatory diseases
Tue, Jun 14, 2022 09:15 CET Report this content
Aqilion is announcing today that the Medicines and Healthcare Products Re... |
| 01.06.2022 | Aqilion strengthens its operational team in clinical development prior to planned Phase I study with drug candidate for inflammatory diseases | Aqilion strengthens its operational team in clinical development prior to planned Phase I study with drug candidate for inflammatory diseases
Wed, Jun 01, 2022 07:30 CET Report this content
Aqilion announced today that the company has recru... |
| 24.05.2022 | Aqilion publishes the Annual Report for 2021 | Aqilion publishes the Annual Report for 2021
Tue, May 24, 2022 07:30 CET Report this content
AQILION AB (publ) hereby announces that the Swedish version of the 2021 Annual Report has been published.
The Annual Report, which is attached in S... |
| 09.05.2022 | Aqilion strengthens its pipeline with a drug candidate in chronic inflammatory bowel diseases, IBD | Aqilion strengthens its pipeline with a drug candidate in chronic inflammatory bowel diseases, IBD
Mon, May 09, 2022 08:30 CET Report this content
Aqilion has nominated Girtab, a program from the company’s research activities, for further p... |
| 19.01.2022 | Aqilion strengthens its operational team in preclinical development | Aqilion strengthens its operational team in preclinical development Wed, Jan 19, 2022 07:30 CET
Aqilion announced today that Anneli Hällgren has been appointed the new head of preclinical development, including regulatory safety studies. An... |
| 21.12.2021 | Aqilion presents Nomination Committee for the 2022 Annual General Meeting | Aqilion presents Nomination Committee for the 2022 Annual General Meeting Tue, Dec 21, 2021 07:30 CET
The Nomination Committee for the 2022 Annual General Meeting has been appointed and comprises the following members: Helena Arcombe, appoi... |
| 06.12.2021 | Aqilion focuses on treatments for inflammatory diseases, updates company pipeline | Aqilion focuses on treatments for inflammatory diseases, updates company pipeline Mon, Dec 06, 2021 08:30 CET
AQILION AB (publ) has decided to expand the Alnitak program by investing resources in a project focused specifically on compounds ... |
| 03.12.2021 | Aqilion strengthens the company’s pipeline through the acquisition of a phase-1 ready anti-inflammatory program from LEO Pharma | Aqilion strengthens the company’s pipeline through the acquisition of a phase-1 ready anti-inflammatory program from LEO Pharma Fri, Dec 03, 2021 14:00 CET
AQILION AB (publ) announced today that it has strengthened its pipeline with an inno... |
| 21.10.2021 | Aqilion presents new preclinical data in the Alnitak program showing unique results in rheumatoid arthritis disease model | Aqilion presents new preclinical data in the Alnitak program showing unique results in rheumatoid arthritis disease model Thu, Oct 21, 2021 07:30 CET
AQILION AB (publ) is presenting preclinical data in the Alnitak program for the first time... |
